Multigenome Retroviral Vectors for Co-Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current retroviral vector systems face challenges in achieving equal expression levels of multiple transgenes due to promoter competition and variability in internal ribosome entry site function, leading to inefficient delivery and antigen processing, particularly in dendritic cells for cancer immunotherapy.
Innovation Solution
Development of recombinant multigenome retroviral vectors and packaging systems that include defective retroviral genomes pseudotyped with heterologous envelope glycoproteins, allowing for controlled co-expression of multiple sequences of interest, such as tumor-associated antigens and immunomodulatory molecules, through controlled dimerization of retroviral vector genomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple transgenes are delivered from a single retroviral vector genome, then gene delivery capability is improved, but expression equality of multiple transgenes deteriorates due to promoter competition and IRES variability
Solution Approach 1:
The invention divides the delivery system into multiple separate retroviral vector genomes, each carrying a single transgene. Instead of attempting to co-express multiple transgenes from one genome (which causes promoter competition), the system uses multiple genomes that can be packaged together in the same viral particle. This segmentation allows each transgene to be expressed independently from its own promoter, eliminating the expression equality problem while maintaining the ability to deliver multiple genes.
2Reliability
If defective retroviral genomes are used for multigenome packaging, then safety is improved by preventing infectious particle production, but vector complexity increases due to need for packaging systems
Solution Approach 1:
The invention extracts the essential packaging functions (gag, pol, env genes) into a separate packaging cell line, leaving the viral vector genomes themselves defective and replication-incompetent. The packaging cell line provides only the necessary structural proteins and enzymes for viral particle assembly, while the transgene-carrying genomes lack the ability to produce infectious particles on their own. This separation improves safety by ensuring the vectors cannot replicate independently, while the complexity is managed through a standardized packaging system.
3Adaptability or versatility
If heterologous envelope glycoproteins are used for pseudotyping, then target cell specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The invention uses a universal packaging cell line that can produce particles with different heterologous envelope glycoproteins by simply transfecting the cell with different envelope gene sequences. The same packaging infrastructure (gag, pol expression, viral assembly machinery) supports multiple envelope types, allowing the system to target different cell types (dendritic cells, T cells, etc.) without redesigning the entire manufacturing process. This multi-functionality maintains ease of manufacture while achieving high target cell specificity.
Data Source
AI summary
The present invention provides novel multigenome retroviral vectors, methods and packaging systems for making such retroviral vectors and methods of use.